As a tumor suppressor, LRP1B mutation was associated with favorable outcomes to immune checkpoint inhibitor across multiple cancer types (Brown et al., 2021), and LRP1B protein was a predictor of response to pegylated liposomal doxorubicin in patients with ovary cancer (Dionisio de Sousa et al., 2021). Here, LRP1B is linked to neoplasm.